Esketamine Safety Protocols: What Clinicians Now Emphasize

What Was Published

A clinical commentary published April 29, 2026 in Psychiatric Times offers a detailed walkthrough of how prescribing clinicians should safely incorporate esketamine nasal spray — sold under the brand name Spravato — into treatment plans for patients with treatment-resistant depression (TRD). The piece, written from a practicing psychiatrist's perspective, covers the practical mechanics of the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, in-office monitoring requirements, vital sign tracking, and the collaborative decision-making process between provider and patient. While the article is aimed at clinicians rather than patients, the protocols described have direct implications for anyone currently receiving or evaluating ketamine-based treatment. Read the original article at Psychiatric Times.

The Clinical Landscape: Esketamine vs. Low-Dose Ketamine

It's worth clarifying a distinction that often confuses patients early in their research. Esketamine (Spravato) is an FDA-approved nasal spray derived from one molecular half of ketamine — the S-enantiomer. It is administered in certified clinical settings under physician supervision and is approved specifically for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Low-dose ketamine infusions, lozenges, and other off-label protocols use racemic ketamine (both S- and R-enantiomers) and operate outside the FDA approval framework for depression, though they are used extensively in clinical practice.

Both approaches share overlapping pharmacology — they work primarily through NMDA receptor antagonism and downstream neuroplasticity mechanisms — but they differ significantly in delivery method, regulatory oversight, dosing precision, and monitoring requirements. The Psychiatric Times piece is specifically about esketamine, but the safety principles it outlines are directly relevant to understanding what responsible low-dose ketamine administration should also look like.

The REMS Program: Why It Exists and What It Requires

The FDA's REMS program for esketamine is not bureaucratic box-checking. It exists because ketamine-class compounds carry real risks: dissociation, sedation, elevated blood pressure, and in rare cases, hemodynamic instability. The REMS program requires that esketamine only be dispensed to patients enrolled in the program, administered in certified healthcare settings, and that patients be monitored for at least two hours after each dose before being cleared to leave.

The two-hour observation window is a hard floor, not a suggestion. During this time, clinicians are expected to track blood pressure, heart rate, and signs of dissociation or sedation at regular intervals. The article emphasizes that patients should not drive or operate heavy machinery on the day of treatment — a restriction that applies equally to IV ketamine infusions and oral ketamine protocols.

For patients considering any form of ketamine treatment, this monitoring framework provides a useful benchmark. If a provider is offering ketamine therapy with minimal post-dose observation time, limited vital sign tracking, or no clear discharge criteria, that is a meaningful red flag regardless of what form of ketamine is being used.

Vitals Monitoring: The Details That Matter

The article is specific about blood pressure being the primary vital sign concern. Ketamine is known to transiently elevate both systolic and diastolic blood pressure, and this effect is dose-dependent. In patients with pre-existing cardiovascular conditions — hypertension, arrhythmias, recent cardiac events — this requires careful pre-screening and potentially more frequent intra-session monitoring.

The clinical recommendation is to take baseline blood pressure before dosing, then recheck at 40 minutes and again before discharge. Some protocols check more frequently. This is consistent with what responsible low-dose ketamine IV infusion centers already practice, and it reinforces why thorough intake screening matters. Patients should expect their provider to ask about cardiovascular history, current medications (especially those affecting blood pressure), and to take a baseline reading at every session — not just the first one.

Referrals and the Role of Collaboration

One underappreciated point in the article is the emphasis on collaborative, patient-centered care and the importance of referrals. Esketamine is rarely a standalone intervention. It is most effective when embedded within a broader treatment plan that includes psychotherapy, medication management, and regular psychiatric follow-up. The article notes that prescribers should be comfortable referring patients to other specialists — cardiologists if blood pressure management is needed, therapists for integration work, or other psychiatric colleagues when symptom complexity exceeds the prescriber's scope.

This collaborative model maps cleanly onto best practices for low-dose ketamine as well. Clinicians who offer ketamine infusions without any coordination with a patient's existing mental health providers, or who resist communication with other treating physicians, are working outside the standard of care that the broader ketamine medicine field is converging on. For patients, this is a practical consideration when evaluating providers: ask explicitly how the clinic communicates with your psychiatrist or therapist, and whether they have a referral network for complex cases.

What This Means for Patients Researching Ketamine Treatment

The publication of detailed clinical guidance like this in a major psychiatry journal reflects a maturing field. In 2026, ketamine and esketamine are no longer fringe interventions — they are part of mainstream psychiatric practice, with growing infrastructure around training, certification, and safety protocols. That is broadly good news for patients, as it raises the floor on what acceptable clinical practice looks like.

For patients who are mid-treatment and finding benefit, this kind of clinical consensus validation is reassuring. The monitoring requirements your clinic follows are not arbitrary; they are grounded in a real understanding of how the drug behaves physiologically and what risks need active management. For patients who are still evaluating whether to start treatment, this guidance underscores the importance of provider selection. The clinical rigor of the setting matters — not as a proxy for efficacy, but as a genuine safety consideration.

One area the article does not address in depth, but which matters significantly for low-dose ketamine patients specifically, is the question of maintenance dosing and long-term monitoring. Both esketamine and racemic ketamine produce antidepressant effects that are typically time-limited, requiring repeat sessions to sustain benefit. How frequently, for how long, and what the indicators are for adjusting or tapering treatment remain areas where clinical guidance is still evolving. Patients and providers should approach maintenance planning collaboratively, with regular reassessment rather than indefinite open-ended continuation.

The evidence base for ketamine in TRD continues to strengthen. The safety infrastructure around it is catching up. That combination — growing efficacy data alongside increasingly standardized safety protocols — is what makes 2026 a meaningfully different moment for ketamine medicine than five years ago.